For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.

By Raechel Thankam Job July 9 (Reuters) - AstraZeneca shares tumbled on Thursday after the company said its nerve disease ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to meet its target ...

By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...

AstraZeneca (LSE:AZN) is back in focus after a recent pullback, with the stock down about 5% over the past month and over the past 3 months, prompting investors to reassess its current valuation. See ...

Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...

Sino Biopharmaceutical inks a licensing deal with AstraZeneca for a respiratory drug, with milestones and royalties worth ...

AstraZeneca's stock tumbled after the pharmaceutical company said its Wainua drug failed to meet the primary target in a late-stage clinical trial for heart disease, denting investor hopes for ...

AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg.

Add Yahoo as a preferred source to see more of our stories on Google. Dr Sue Pavord:’It was scary. I was a mother of three kids in their 20s, and these were the people we were seeing dying’ - ...

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...